

Isovaleric acid



Ammonium isovalerate



Isovaleramide



N-Ethyl isovaleramide



Ethyl isovalerate



Glyceryl triisovalerate ("Triisovalerin")



Glyceryl-1,3-diisovalerate



Glyceryl-1,2-diisovalerate



Glyceryl-1-monoisovalerate



Glyceryl-2-monoisovalerate



N-Isovaleryl GABA



N-Isovaleryl glycine



Isovaleryl salicylic acid ("I.S.A."); salicylic acid isovalerate



β-Sitosteryl isovalerate



Isovaleryl salicylamide (salicylamide isovalerate ester)



"Isovaleraminophen" [*N*-(4-hydroxyphenyl)-isovaleramide]



Valproic acid



Valpromide



Isovaleryl-acetaminophen ester

Figure 1a. The Structures of Isovaleramide and Related Compounds.



Figure 1b: Structures of compounds structurally related to isovaleramide

Figure 2.

NPS 1776 Formulation II (Coated 400 mg Tablet)
Clinical Batch Dissolution in SGF only (n=1), SIF only (n=1), and 2 Stage Media (n=6)



Figure 3. NPS 1776 Formulation III (Coated 600 mg Tablet)
Development Batch Dissolution in SGF only (n=1), SIF only (n=1), and 2 Stage Media (n=2)



Figure 4. NPS 1776 Release From Coated MPC Formulations



Figure 5. NPS 1776 Release From Coated MPC Formulations